Assoc Prof George has been at the University of Technology since its inception as a university in 1989. He has published over 60 papers. He graduated with a PhD degree from the University of Sydney in 1981 and completed postdoctoral fellowships at Tufts University Medical School (Boston) and the John Curtin School of Medical Research (Canberra).

His tenured academic position at UTS began in 1986. His early research was focused on multidrug resistance in pathogenic bacteria and this work continued at UTS, which more recently has moved into the study of pathogenic infections in serious medical syndromes such as cystic fibrosis.

A/P George's research has taken two new directions, one beginning in 1995 and the second in 2007. In 1996, A/P George published the first and still only successful cloning, expression, and drug efflux for human P-glycoprotein in Eschericia coli. This MDR protein belongs to one of the largest gene/protein families in all species, namely ABC transporters. Most of his work since then has involved structure-function studies of ABC transporters, using traditional laboratory methods and the emerging and powerful computational molecular dynamic simulations that take X-ray crystal structures of proteins and "animate" them in computers to explore their function. We have been very successful in this field, having discovered the dimeric structural configuration of ABC transporters and elaborated a new model for the function of these proteins. A/P George's work has been rewarded by prestigious invitations to give keynote talks at international conferences, to Chair a Gordon Research Meeting on multidrug resistance systems and invited on to the Scientific Advisory Board of the FEBS ABC Efflux Meetings, held every two years in Austria.

A/P George has published trailblazing studies and many scholarly reviews in high impact journals such as Proc Natl Acad Sci USA and Trend Biochem Sci. He has supervised many Honours, Masters, and PhDs, and has a Research Associate of long standing for his mainstream ABC transporter research. Total research funding and fellowships for all projects exceeds $5m.

In 2007, A/P George began a new project intended to alleviate the onset and progression of incurable asbestos-related diseases. Research began by studying the effects of asbestos fibres and counteracting agents in human lung cells; and has moved these past years to an animal model. The work has been rewarded with a Trailblazer Award (2008) and with substantial funding ($712,000) from philanthropic sources. The mouse model work has illustrated remarkable success in slowing or preventing the onset of mesothelioma, an incurable disease. A provisional patent on our new treatment has recently been converted to a full patent. Presently, we are seeking funding to take the project to a first human trial in 2017.